# Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

> **NCT01817959** · PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 51 (actual)

## Conditions studied

- Islet Transplantation in Diabetes Mellitus Type 1

## Interventions

- **DRUG:** Reparixin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01817959
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817959, "Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01817959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*